Medline (NASDAQ:MDLN) Hits New 1-Year Low – Here’s What Happened

Posted by Brenda Bartman on Aug 20th, 2026

Shares of Medline (NASDAQ:MDLN – Get Free Report) hit a new 52-week low during trading on Thursday . The stock traded as low as $32.76 and last traded at $32.89, with a volume of 3161926 shares trading hands. The stock had previously closed at $33.91.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. BNP Paribas Exane dropped their price target on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on shares of Medline in a report on Thursday, August 6th. Tigress Financial cut their price target on Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Royal Bank Of Canada lowered their price objective on Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus lowered their price target on Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medline presently has an average rating of “Moderate Buy” and a consensus price target of $47.42.

Check Out Our Latest Stock Report on MDLN

Medline Stock Performance

The stock has a market cap of $43.25 billion and a PE ratio of 41.65. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average price of $38.23 and a 200 day moving average price of $41.14.

Medline (NASDAQ:MDLN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. As a group, research analysts forecast that Medline will post 1.51 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Douglas P. Golwas sold 100,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the transaction, the insider owned 23,899 shares of the company’s stock, valued at $878,766.23. The trade was a 80.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Private Ltd Gic sold 1,976,618 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80. Following the sale, the insider directly owned 25,264,760 shares in the company, valued at approximately $899,425,456. This trade represents a 7.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 4,538,896 shares of company stock valued at $161,936,454. 0.81% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MDLN. Mass General Brigham Inc raised its position in Medline by 167.6% during the first quarter. Mass General Brigham Inc now owns 70,357 shares of the company’s stock worth $3,131,000 after acquiring an additional 44,063 shares during the period. Cetera Investment Advisers boosted its position in Medline by 128.4% during the first quarter. Cetera Investment Advisers now owns 52,088 shares of the company’s stock worth $2,318,000 after acquiring an additional 29,282 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Medline in the first quarter valued at approximately $1,177,000. UBS Group AG purchased a new stake in Medline in the 4th quarter valued at $54,707,000. Finally, Pictet Asset Management Holding SA acquired a new stake in Medline during the fourth quarter worth about $48,996,000.

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.